WHO ICTRP trial
Bioequivalence study of Ibrutinib 140 mg
IRCT20200105046010N78 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20200105046010N78 |
|---|---|
| Public title | Bioequivalence study of Ibrutinib 140 mg |
| Scientific title | Bioequivalence study of Ibrutinib 140 mg capsule (Lifoza) manufactured by Dr. Abidi company versus Imbruvica 140 mg in healthy volunteers in the fasted condition |
| Primary sponsor | Tabriz University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | This study is performed on healthy volunteers.. |
| Interventions | Intervention 1: Intervention group: single dose, one oral capsule 140mg(Imbruviva) manufactured by Janssen, as a reference product. Intervention 2: Intervention group: Single dose, one oral Lifoza 140 mg capsule manufactured by Dr. Abidi… |
| Registration date | Jul 4, 2023 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: